The market is very small in the US and Europe, but possibly revenue neutral in Asia, where the disease is more prevalent.
Comparing PI-88 to Avastin is unfair, with PI-88 now completely missing the endpoints on its first trial outside the liver cancer indication. It is worrysome that there is no detectable cancer-fighting activity, and this is strongly suggestive of Phase III failure, in my view. If the mechanism was sound for liver cancer, then some activity - any activity - would have been reported for lung cancer.
The future of PI-88 as a viable drug for multiple conditions is now dead. It is time to cut their losses, and try to find a lead that can actually generate meaningful revenue.
Strong sell.
- Forums
- ASX - By Stock
- PGL
- lung cancer trial fails
lung cancer trial fails, page-12
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PGL (ASX) to my watchlist
|
|||||
Last
44.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.30M |
Open | High | Low | Value | Volume |
44.5¢ | 44.5¢ | 44.0¢ | $226.2K | 509.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 158238 | 44.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.0¢ | 257803 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 158238 | 0.445 |
8 | 959885 | 0.440 |
1 | 22800 | 0.435 |
3 | 8500 | 0.350 |
1 | 2500 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.450 | 257803 | 9 |
0.460 | 100000 | 1 |
0.490 | 21811 | 2 |
0.500 | 2000 | 1 |
0.000 | 0 | 0 |
Last trade - 15.23pm 23/07/2024 (20 minute delay) ? |
Featured News
PGL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online